Enovis Corporation (NYSE: ENOV) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -19.40 | Insider Own | 9.09% | Shs Outstand | 57.56M | Perf Week | -6.43% |
| Market Cap | 1.04B | Forward P/E | 4.89 | EPS next Y | 3.69 | Insider Trans | 0.53% | Shs Float | 56.59M | Perf Month | -31.92% |
| Enterprise Value | 2.37B | PEG | - | EPS next Q | 0.76 | Inst Own | - | Short Float | 16.07% | Perf Quarter | -17.89% |
| Income | -1.10B | P/S | 0.45 | EPS this Y | 118.76% | Inst Trans | - | Short Ratio | 8.16 | Perf Half Y | -20.07% |
| Sales | 2.30B | P/B | 0.70 | EPS next Y | 1.45% | ROA | -29.25% | Short Interest | 9.09M | Perf YTD | -32.28% |
| Book/sh | 25.69 | P/C | 79.89 | EPS next 5Y | 8.28% | ROE | -68.17% | 52W High | 34.28 -47.37% | Perf Year | -43.85% |
| Cash/sh | 0.23 | P/FCF | 17.43 | EPS past 3/5Y | - | ROIC | 2.95% | 52W Low | 17.30 4.28% | Perf 3Y | -66.23% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 12.88% 14.93% | Gross Margin | 57.43% | Volatility | 6.75% 5.90% | Perf 5Y | -77.36% |
| Dividend TTM | - | EV/Sales | 1.03 | EPS Y/Y TTM | -29.94% | Oper. Margin | 4.14% | ATR (14) | 1.34 | Perf 10Y | -65.03% |
| Dividend Ex-Date | - | Quick Ratio | 1.00 | Sales Y/Y TTM | 8.97% | Profit Margin | -47.97% | RSI (14) | 33.97 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.98 | EPS Q/Q | 13.92% | SMA20 | -14.60% | Beta | 1.15 | Target Price | 38.20 |
| Payout | 0.00% | Debt/Eq | 0.92 | Sales Q/Q | 3.19% | SMA50 | -26.88% | Rel Volume | 1.55 | Prev Close | 17.80 |
| Employees | 7,802 | LT Debt/Eq | 0.88 | Earnings | Nov 05 | SMA200 | -25.65% | Avg Volume | 1.41M | Price | 18.04 |
| IPO Date | May 08, 2008 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.27% 0.16% | Net Debt/EBITDA | -1.89 | Volume | 2,199,994 | Change | 1.35% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-01-26 | Reiterated | BMO Capital | $30 → $27 | |
| Sep-01-26 | Reiterated | BTIG | Buy | $41 → $36 |
| Aug-17-26 | Reiterated | Canaccord Genuity | Buy | $50 → $45 |
| Aug-07-26 | Reiterated | BMO Capital | $29 → $30 | |
| Jul-28-26 | Reiterated | UBS | Buy | $50 → $51 |
| Jul-08-26 | Initiated | BMO Capital | Outperform | $29 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $36 → $32 |
| May-08-26 | Reiterated | Evercore ISI Group | Outperform | $40 → $36 |
| Feb-26-26 | Reiterated | Needham | Buy | $65 → $52 |
| Jan-06-26 | Initiated | BTIG | Buy | $41 |
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,297 | 2,248 | 2,108 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 978 | 903 | 927 | — | — | — | — | — | — | |
| Gross Profit | 1,319 | 1,345 | 1,181 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,054 | 1,070 | 939 | — | — | — | — | — | — | |
| Research and Development | 125 | 120 | 91 | — | — | — | — | — | — | |
| Other Operating Expense | 45 | 174 | 926 | — | — | — | — | — | — | |
| Operating Income | 94 | -19 | -776 | — | — | — | — | — | — | |
| Interest Expense | 56 | 35 | 57 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1,107 | -1,106 | 10 | — | — | — | — | — | — | |
| Net Income Before Taxes | -1,069 | -1,159 | -823 | — | — | — | — | — | — | |
| Income Taxes | 31 | 22 | 4 | — | — | — | — | — | — | |
| Consolidated Net Income | -1,102 | -1,184 | -825 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,099 | -1,182 | -827 | — | — | — | — | — | — | |
| Net Income | -1,102 | -1,184 | -825 | — | — | — | — | — | — | |
| EPS (Recurring) | -19.40 | -20.86 | -14.93 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -19.40 | -20.86 | -14.93 | — | — | — | — | — | — | |
| EPS (Diluted) | -19.40 | -20.86 | -14.93 | — | — | — | — | — | — | |
| EBITDA | -717 | -830 | -481 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.46 | 0.68 | 1.14 | — | — | — | — | — | — | |
| Gross Margin | 57.42 | 59.83 | 56.02 | — | — | — | — | — | — | |
| Operating Margin | 4.09 | -0.85 | -36.81 | — | — | — | — | — | — | |
| Net Margin | -47.98 | -52.67 | -39.14 | — | — | — | — | — | — | |
| Shares Outstanding | 58 | 57 | 55 | — | — | — | — | — | — | |
| Market Capitalization | 1,046 | 1,518 | 2,413 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Engert Oliver | Chief Administrative Officer | Sep 04 '26 | Buy | 18.80 | 2,660 | 50,008 | 63,898 | Sep 08 |
| McDonald Damien | Chief Executive Officer | Sep 04 '26 | Buy | 19.15 | 13,035 | 249,620 | 247,077 | Sep 04 |
| Engert Oliver | Chief Administrative Officer | Sep 03 '26 | Buy | 19.46 | 5,140 | 100,024 | 61,238 | Sep 04 |
| Engert Oliver | Chief Administrative Officer | Sep 02 '26 | Buy | 20.32 | 2,458 | 49,947 | 56,098 | Sep 04 |
| Engert Oliver | Chief Administrative Officer | Jun 15 '26 | Buy | 20.92 | 1,000 | 20,920 | 53,640 | Jun 16 |
| Engert Oliver | Chief Administrative Officer | Jun 11 '26 | Buy | 21.62 | 1,200 | 25,948 | 51,840 | Jun 15 |
| Engert Oliver | Chief Administrative Officer | Jun 10 '26 | Buy | 23.00 | 1,000 | 23,000 | 50,640 | Jun 11 |
| Engert Oliver | Chief Administrative Officer | Jun 01 '26 | Buy | 22.22 | 1,000 | 22,220 | 49,640 | Jun 03 |
| Engert Oliver | Chief Administrative Officer | Mar 13 '26 | Buy | 23.74 | 1,000 | 23,740 | 48,640 | Mar 16 |
| Engert Oliver | Chief Administrative Officer | Mar 10 '26 | Buy | 23.93 | 1,000 | 23,930 | 47,640 | Mar 12 |
| Engert Oliver | Chief Administrative Officer | Mar 09 '26 | Buy | 23.39 | 1,000 | 23,390 | 46,640 | Mar 10 |
| Engert Oliver | Chief Administrative Officer | Mar 06 '26 | Buy | 24.41 | 750 | 18,310 | 45,640 | Mar 10 |
| Engert Oliver | Chief Administrative Officer | Mar 04 '26 | Buy | 25.10 | 250 | 6,275 | 44,890 | Mar 05 |
| Engert Oliver | Chief Administrative Officer | Mar 03 '26 | Buy | 24.77 | 1,000 | 24,770 | 44,640 | Mar 05 |
| Engert Oliver | Chief Administrative Officer | Feb 27 '26 | Buy | 25.50 | 1,000 | 25,500 | 43,640 | Mar 03 |